Abstracts tagged "treatment and tumor necrosis factor (TNF)"

Abstract Number: 1145 • 2014 ACR/ARHP Annual Meeting
Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post-Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², A. Koenig³ and J. Bourret³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: For rheumatoid arthritis (RA) patients (pts) with inadequate response to a TNF inhibitor (TNFi), limited evidence exists from observational studies and indirect comparisons of…
Abstract Number: 472 • 2013 ACR/ARHP Annual Meeting
Clinical Efficacy Rate Of The Non-Specific Effect (the placebo effect) In The Tumour Necrosis Factor Inhibitors For Rheumatoid Arthritis Treatment After Methotrexate Failure: Meta-Analysis
Julie Azaïs¹, Thomas Barnetche², Pascale Vergne-Salle³, Christine Bonnet⁴, Carine Dufauret-Lombard⁵, Richard Treves⁶ and Philippe Bertin⁷, ¹Rheumatology department, CHU Dupuytren Limoges, Limoges, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, CHU Dupuytren Limoges, limoges, France, ⁴department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁵Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁶Department of Rheumatology, CHU Dupuytren Limoges, Limoges, France, ⁷Service De Rhumatologie, CHU Dupuytren Limoges, Limoges, France
Background/Purpose: Therapeutics generate non-specific effects (the placebo effect), and specific ones, like the 5 tumor necrosis factor (TNF) inhibitors used in the treatment of Rheumatoid…
Abstract Number: L12 • 2013 ACR/ARHP Annual Meeting
Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Demonstrates Efficacy and Significantly Reduces Proinflammatory Cytokines in Patients with Active Longstanding Rheumatoid Arthritis with High Gonadotropin Levels: A Proof-of-Concept, Double-Blind, Randomized Trial
Anita Kåss^1,2, Ivana Hollan³, Peter Torjesen⁴, Hans Christian Gulseth⁵ and Øystein T. Førre⁶, ¹Faculty of Medicine, University of Oslo, Oslo, Norway, ²Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ³Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁴Department of Endocrinology, Oslo University Hospital, Oslo, Norway, ⁵Rheumatology, Betanien Hospital, Skien, Norway, ⁶Oslo University Hospital, Oslo, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and treatment options can be improved. Gonadotropin-releasing hormone (GnRH) stimulates immune responses (1). Inhibiting GnRH, by…
Abstract Number: 2801 • 2013 ACR/ARHP Annual Meeting
Comparative Longitudinal Analysis Of Periarticular Bone Structure In Patients Treated With Methotrexate In Combination Of Either TNF Blockers Or Tocilizumab
Sebastian Kraus¹, Matthias Englbrecht¹, Juergen Rech², Roland Kocijan¹, Georg A. Schett¹ and Stephanie Finzel¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Inhibition of tumor necrosis factor alpha (TNFi) and interleukin-6 receptor (IL6Ri, tocilzumab) are among the most potent therapeutic strategies in patients with rheumatoid arthritis…
Abstract Number: 2354 • 2013 ACR/ARHP Annual Meeting
Drug Survival Rates Of Anti-Tumor Necrosis Factor Therapies In Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
Dong-Jin Park¹, Kyung-Eun Lee¹, Ji-Hyoun Kang², Jeong-Won Lee², Tae-Jong Kim³, Yong-Wook Park¹ and Shin-Seok Lee⁴, ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Chonnam National University Medical School, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: We investigated the compliance of Korean patients using anti-tumor necrosis factor (TNF) agents to treat rheumatoid arthritis (RA) and anklyosing spondylitis (AS), and identified…
Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Bente Glintborg¹, Mikkel Østergaard², Niels Steen Krogh³, Martin Dehn Andersen⁴, Ulrik Tarp⁴, Anne Gitte Loft⁴, Hanne M. Lindegaard⁵, Mette Holland-Fischer⁶, Henrik Nordin⁴, Dorte Vendelbo Jensen⁴ and Merete L. Hetland², ¹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…
Abstract Number: 2540 • 2012 ACR/ARHP Annual Meeting
Prescription of Tumour Necrosis Factor α Antagonists Is Strongly Associated with a Reduction in Hospital Admissions and in Musculoskeletal Surgical Procedures for Rheumatoid Arthritis Based On a 16 Year Analysis of Nationwide Data
Leonard C. Harty¹, Gary O'Toole², Kathleen Bennett³ and Oliver M. FitzGerald⁴, ¹Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Orthopaedic Surgery, St. Vincent's University Hospital, Dublin, Ireland, ³Trinity Centre for Health Sciences, Department of Pharmacology & Therapeutics, Dublin, Ireland, ⁴Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Comorbidities, joint destruction leading to orthopaedic intervention and physical disability are predictable outcomes of uncontrolled Rheumatoid Arthritis (RA). Synthetic DMARDS have a slow mechanism…
Abstract Number: 2152 • 2012 ACR/ARHP Annual Meeting
Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production
Jun Li¹, Hui-Chen Hsu², PingAr Yang¹, Qi Wu¹, David M. Spalding³, W. Winn Chatham⁴, Robert P. Kimberly⁵, S. Louis Bridges Jr.⁶ and John D. Mountz⁷, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Clinical Immunology & Rheum, University of Alabama at Birmingham, Birmingham, AL, ⁷Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL
Background/Purpose: Fucosylation, catalyzed by fucosyltransferases (Futs), is an important glycosylation process involved in inflammation, cell death, and differentiation. We have observed an extremely high positive correlation…
Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Vibeke Strand¹, Thomas V. Jones², Wenzhi Li³, Andrew S. Koenig⁴ and Sameer Kotak⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ⁵Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 1338 • 2012 ACR/ARHP Annual Meeting
Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation
M.M. Herenius¹, A.S.F. Oliveira¹, C.A. Wijbrandts¹, D. Gerlag¹, Paul P. Tak² and Maria C. Lebre³, ¹Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular matrix proteins and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].